Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 17/20 | 0.69 |
| ▸ | NR1H3 | Q13133 | 17/20 | 0.69 |
| ▸ | POLA1 | P09884 | 2/20 | 0.51 |
| ▸ | SOD1 | P00441 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552174 | 0.94 | NR1H2 (0.77) | NR1H2NR1H3POLA1SOD1 | |
| SCHEMBL20560970 | 0.89 | NR1H2 (0.87) | NR1H2NR1H3SOD1 | |
| SCHEMBL24270940 | 0.89 | NR1H2 (0.87) | NR1H2NR1H3SOD1 | |
| SCHEMBL23962014 | 0.89 | NR1H2 (0.87) | NR1H2NR1H3SOD1 | |
| SCHEMBL21552124 | 0.89 | NR1H2 (0.66) | NR1H2NR1H3POLA1 | |
| SCHEMBL24591697 | 0.88 | NR1H2 (0.67) | NR1H2NR1H3POLA1SOD1 | |
| SCHEMBL24270700 | 0.87 | NR1H2 (0.66) | NR1H2NR1H3 | |
| SCHEMBL27954309 | 0.86 | NR1H2 (0.64) | NR1H2NR1H3POLA1SOD1 | |
| SCHEMBL24591757 | 0.86 | NR1H2 (0.64) | NR1H2NR1H3POLA1 | |
| SCHEMBL20561450 | 0.84 | CYP3A4 (0.70) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR1H2 195/4885NR1H3 128/4885POLA1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.